Blog Post from the ALS Association

AB Science Announces a Voluntary Hold in the Clinical Studies of Masitinib

Masitinib

We received news that AB Science has paused its masitinib studies worldwide, including its phase 3 ALS trial. The company’s announcement of this breaking news can be found here.

Join the conversation. Please comment below.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
June 3, 2021
Article Topic
Research
Print Friendly and PDF